NASDAQ:REPL

Replimune Group Stock Insider Trading

Healthcare > Biotechnology

Buy REPL

*Your capital is at risk

$9.98

+1.11 (+12.51%)

At Close: Jun 03, 2026

Replimune Group Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 91.82. In total, the insiders bought 29.84M and sold 318.58K REPL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	91.82
● Buy	29.84M shares
● Sell	318.58K shares
74% Buy Activity Moderate Negative Correlation
Sell Signal Low Confidence May 18, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 91.82. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Sell	Common Stock S-Sale	Hill Emily Luisa Chief Financial Officer	C-Suite Officer	7 812 Value: $39.7K
May 18, 2026 Sell	Common Stock S-Sale	Astley-sparke Philip Director	Director	17 657 Value: $89.7K
May 18, 2026 Sell	Common Stock S-Sale	Sarchi Christopher Chief Commercial Officer	Officer	8 626 Value: $43.8K
May 18, 2026 Sell	Common Stock S-Sale	Xynos Konstantinos Chief Medical Officer	Officer	14 023 Value: $71.2K
May 18, 2026 Sell	Common Stock S-Sale	Schwendenman Andrew Chief Accounting Officer	Officer	7 894 Value: $40.1K
May 18, 2026 Sell	Common Stock S-Sale	Patel Sushil Chief Executive Officer	CEO / President	37 324 Value: $189.6K
Apr 02, 2026 Sell	Common Stock S-Sale	Sarchi Christopher Chief Commercial Officer	Officer	6 500 Value: $52.1K
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Weinand Dieter Director	Director	44 500 Value: $338.6K
Apr 01, 2026 Buy	Employee Stock Option (right to buy) A-Award	Hill Emily Luisa Chief Financial Officer	C-Suite Officer	75 000 Value: $570.8K
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Slattery Joseph P Director	Director	44 500 Value: $338.6K
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Dhingra Kapil Director	Director	44 500 Value: $338.6K
Apr 01, 2026 Buy	Common Stock A-Award	Patel Sushil Chief Executive Officer	CEO / President	251 240 Value: $1.91M
Apr 01, 2026 Buy	Common Stock A-Award	Schwendenman Andrew Chief Accounting Officer	Officer	36 667 Value: $279.0K
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Balachandran Madhavan Director	Director	44 500 Value: $338.6K
Apr 01, 2026 Buy	Employee Stock Option (right to buy) A-Award	Xynos Konstantinos Chief Medical Officer	Officer	75 000 Value: $570.8K
Apr 01, 2026 Buy	Common Stock A-Award	Xynos Konstantinos Chief Medical Officer	Officer	50 000 Value: $380.5K
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Oliger Christy J. Director	Director	44 500 Value: $338.6K
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Astley-sparke Philip Director	Director	75 000 Value: $570.8K
Apr 01, 2026 Buy	Common Stock A-Award	Astley-sparke Philip Director	Director	50 000 Value: $380.5K
Apr 01, 2026 Buy	Non-Qualified Stock Option (right to buy)uy) A-Award	Baker Bros. Advisors Lp	Director	44 500 Value: $338.6K
Apr 01, 2026 Buy	Common Stock A-Award	Sarchi Christopher Chief Commercial Officer	Officer	50 000 Value: $380.5K
Apr 01, 2026 Buy	Employee Stock Option (right to buy) A-Award	Sarchi Christopher Chief Commercial Officer	Officer	75 000 Value: $570.8K
Apr 01, 2026 Buy	Employee Stock Option (right to buy) A-Award	Schwendenman Andrew Chief Accounting Officer	Officer	55 000 Value: $418.6K
Apr 01, 2026 Buy	Employee Stock Option (right to buy) A-Award	Patel Sushil Chief Executive Officer	CEO / President	376 860 Value: $2.87M
Apr 01, 2026 Buy	Stock Option (right to buy) A-Award	Pucci Paolo Director	Director	44 500 Value: $338.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT REPLIMUNE GROUP INC.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Pha...

Read Full Profile Here